Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Valerates”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 559 records · Page 31Linked to original sources
PubMed1987

A clinical trial using a regimen which includes a norgestomet implant and norgestomet plus oestradiol valerate injection as a treatment for anoestrus in dairy cows.

In seasonally calving dairy herds in the Macalister Irrigation Area of Gippsland, Victoria, cows that had not been observed in oestrus by the start of the mating season and which had inactive ovaries based on rectal palpation and progesterone assay were treated with a hormonal treatment (n = 49). Mature cows had calved at least 40 days previously and 2-year-olds had been calved at least 60 days. The treatment consisted of a norgestomet implant and a norgestomet and oestradiol injection on day 1; prostaglandin analogue Prosolvin) on day 8; withdrawal of implant on day 10 and an injection of PMSG; and fixed time artificial insemination 54 to 56 h after implant withdrawal. This treatment was called the Syncro-mate regimen. Control cows (n = 46) were injected with water on days 1, 8 and 10 and artificially inseminated or served by a bull when seen on heat. Forty seven percent of the treated cows became pregnant within 14 days from the start of treatment compared with 20% of control cows (P less than 0.01). There was an effect of age group on the response to treatment. A greater proportion of 2-year-old cows than mature cows became pregnant within 14 days of treatment (79% of 19 v. 27% of 20; Chi square interaction, treatment by age, 6.4, P less than 0.05). In the younger cows there was also a gain of 22 days in the treatment to conception interval over the control cows (P less than 0.001). It was concluded that the Syncro-mate regimen can be an effective treatment for post partum anoestrus in dairy cows under certain conditions.

Anestrus↗
PubMed1980

A rapid and simple gas-liquid chromatographic determination of valproic acid (alpha-propyl-valeric acid) in serum.

A simple and rapid gas-liquid chromatographic method for the determination of valproic acid in serum is described. Valproic acid is extracted from acidified serum into chloroform and analyzed by gas-liquid chromatography using an FFAP column. The sensitivity of the method is 5 mumol/l and the within-run and day-to-day precisions (CV) are 4.5% or better. Analytical recovery is estimated to exceed 98% and no interference from other drugs or constituents of serum has been observed. The method was used to study the half-life of valproic acid in five healthy persons receiving a single oral dose of the drug, and the technique is well adapted to the routine monitoring of epileptic patients. In routine analysis, the determination of 50 serum samples may be performed by one technician during a normal working day.

Epilepsy↗
PubMed1996

Effect of prostaglandin F2 alpha administered before estrus synchronization with norgestomet and estradiol valerate on calving rates of beef cows.

Three experiments were conducted to evaluate the effects of prostaglandin F2 alpha treatments 5, 9, and 14 d before Syncro-Mate B on calving rates of 1,072 beef cows from inseminations at a pre-set time. The administration of prostaglandin F2 alpha 5 d before Syncro-Mate B decreased (P < .01) calving rates. This reduction was associated with lower (P < .05) calving rates in cows administered Syncro-Mate B in the first half of the estrous cycle. Calving rates were unaffected n cows administered prostaglandin F2 alpha 9 d before Syncro-Mate B. The administration of prostaglandin F2 alpha 14 d before Syncro-Mate B reduced (P < .05) calving rates in previously anestrous cows. In summary, prostaglandin F2 alpha should not be administered to postpartum cows 5 to 14 d before Syncro-Mate B synchronization.

Animals↗
PubMed1997

Effects of estradiol valerate on growth hormone and prolactin response to growth hormone-releasing hormone stimulation in pre- and postmenopausal women.

We investigated the relationship between the growth hormone and prolactin response to stimulation of growth hormone-releasing hormone (GHRH) and changes in body weight in pre- and postmenopausal women before and after 4 and 20 weeks of oral hormone replacement therapy (HRT). Ten postmenopausal women (with levels of follicle-stimulating hormone (FSH) of > 30 mIU/ml) were compared to ten premenopausal women suffering from post-pill amenorrhea (FSH < 10 mIU/ml). Both patient groups reported anamnestic body weight increases in the course of the former use of sex hormones. Additionally, ten postmenopausal women without anamnestic weight changes were studied. A significant reduction in the growth hormone response to GHRH was observed during the first month of HRT in women gaining weight, which was restored to pre-therapeutic levels after 6 months of HRT. A small but statistically significant increase in insulin-like growth factor (IGF)-I levels occurred in the course of HRT in all patients studied. These changes in growth hormone stimulation testing and IGF-I levels were accompanied by distinct changes in body weight. No reduction in the GHRH response was observed in those patients who did not gain body weight. Although GHRH stimulation induces a significant rise of prolactin concentrations in all patients before therapy no influence on prolactin levels could be demonstrated during HRT.

Adolescent↗
PubMed2000

[Comparative study between estradiol valerate combined with cyproterone acetate, and conjugated equine estrogens combined with medroxyprogesterone acetate as hormone replacement therapy in climacteric].

OBJECTIVE: To compare the effectiveness in the control of climacteric symptoms, the tolerability and the uterine bleeding pattern between two types of hormone replacement therapy. MATERIAL AND METHODS: 81 postmenopausal women between 40 and 60 years age with vasomotor symptoms were studied. Randomly it was administered: I. Conjugated equine estrogens (CEE)-Medroxyprogesterone acetate (MPA): 21 tablets with 0.625 mg of CEE and 10 tablets with 5 mg of MPA which were taken with the last ten tablets of CEE in each cycle (n = 3 7). II. E2V-CPA: 11 tablets with 2 mg of E2V and 10 tablets with 2 mg of E2V and 1 mg of CPA (n = 44). Each cycle comprised 28 days. The treatments were compared with squared Chi and Mann-Whitney U test. RESULTS: The hot flushes presence was significantly greater in the group with CEE-MPA (p < 0.03). Severe throbs at the end of the study had a trend to be more frequent in the group with EC-MPA (p < 0.06). At the end of the study there was a greater frequency of breast tenderness in the group with CEE-MPA (P = 0.009). CONCLUSIONS: Both treatments have good effectiveness, tolerability and same bleeding pattern. Only the frequency of hot flushes, the presence of severe throbs and breast tenderness were lower in the group with E2V-CPA, that makes this preparation an option that can have a better acceptance by the women.

Adult↗